Greenwich LifeSciences (GLSI) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Pyxis Oncology (PYXS) over the past year, gaining 32.3% versus a loss of 31.6%. Over five years, GLSI leads with a -60.1% price change compared with -83.1% for PYXS. Pyxis Oncology is the larger company by market cap ($241.9 million vs $234.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | PYXS |
|---|---|---|
| Share price | $16.00 | $2.03 |
| Market cap | $234.85M | $241.90M |
| 1-day change | +5.68% | +1.76% |
| YTD return | -27.94% | +73.04% |
| 1-year return | +32.28% | -31.62% |
| 5-year return | -60.12% | -83.09% |
| EPS (TTM) | $-1.53 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $5.55 |
| 52-week low | $7.78 | $1.03 |
| Distance from 52-week high | -53.08% | -63.51% |
| Analyst consensus | none | none |
| Avg. price target upside | +256.25% | +328.15% |
| Average volume | 138.91K | 1.26M |
| Shares outstanding | 14.68M | 119.46M |
| Employees | — | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed PYXS by 63.9 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
GLSI vs PYXS FAQ
Which is bigger, Greenwich LifeSciences or Pyxis Oncology?
Pyxis Oncology (PYXS) is larger, with a market capitalization of $241.90M compared with $234.85M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, GLSI or PYXS?
GLSI returned +32.28% over the past 12 months, compared with -31.62% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.